Clinical Oncology - 2024;11(1)

Clinical Oncology

FEBRUARY 29, 2024

[News from around the world]

[ ]

HUN 2024;11(1)

Clinical Oncology

FEBRUARY 29, 2024

[New treatment paradigms in advanced stage cervical cancer]

SZÖLLŐSI Regő

[Cervical cancer is still a global health problem, being the fourth most common cancer in incidence and mortality in women worldwide. Most of the cases are associated with HPV 16/18 infection.]

HUN 2024;11(1)

Clinical Oncology

FEBRUARY 29, 2024

[Current medical treatment of colon cancer]

LAKATOS Gábor

[Colorectal cancer is one of the most common and lethal malignancies in developed countries. Over the past years, substantial advances have been made in the treatment of patients with both localised and metastatic disease.]

HUN 2024;11(1)

Clinical Oncology

FEBRUARY 29, 2024

[The summary of the San Antonio Breast Cancer Symposium 2023]

MÁHR Károly

[Each year, breast cancer professionals eagerly await the latest results from the San Antonio Breast Cancer Symposium. There was also great interest in the symposium in December 2023. In addition to the primary results of the recently started studies, many people were also waiting for the latest data from the previously described clinical studies.]

HUN 2024;11(1)

Clinical Oncology

FEBRUARY 29, 2024

[Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up]

T. Conroy, P. Pfeiffer, V. Vilgrain, A. Lamarca, T. Seufferlein, E. M. O’Reilly, T. Hackert, T. Golan, G. Prager, K. Haustermans, A. Vogel, M. Ducreux

[The possibility of detecting pancreatic cancer (PC) at a potentially curable stage depends on early diagnosis and the ability to identify and screen high-risk populations before symptoms appear. Identifying high-risk populations is challenging and optimal screening tools remain unclear (1).]

HUN 2024;11(1)

Clinical Oncology

FEBRUARY 29, 2024

[Phenotypic plasticity and immunogenic mimicry of cancer]

TÍMÁR József, KENNETH V. Honn, MARY J. C. Hendrix, MARKO-VARGA György, SIRPA Jalkanen

[It is a newly recognized hallmark of cancer, the phenotypic plasticity comprising of (epithelial) mesenchymal transition, vasculogenic- and megakariocytic mimicries. It is well known that immune escape of cancers may relay on the ectopic expression of PDL1 (or CTLA4).]

HUN 2024;11(1)

Clinical Oncology

FEBRUARY 29, 2024

[Quantifiying sarcopenia with computered tomography in oncology patients]

KOSTYÁL László, TORNYI Ilona, FURKA Andrea

[Sarcopenia is a condition associated with a change in muscle composition, a progressive decrease in muscle strength and muscle mass, which can harm the prognosis of cancer patients.]

HUN 2024;11(1)

Clinical Oncology

FEBRUARY 29, 2024

[Pharmacovigilance landscape – Lessons from the past and opportunities for future]

BALÁZS Máté Ádám, DANK Magdolna

[Pharmacovigilance is a dynamically developing new scientific field as well as an important industrial and regulatory field. The development of pharmacovigilance was facilitated by incidents such as the disaster of thalidomide in the 1950s and 1960s or the scandal of fatal drug side effects caused by benoxaprofen in 1982.]

HUN 2024;11(1)